|
|
|
| PROJECT TITLE | Prenylation Inhibitors as Novel Antiviral Agents |
| CATEGORY | Virus, Liver disease |
| PROJECT DESCRIPTION |
This
research provides the first human clinical trial of new way to treat
viral diseases such as Hepatitis Delta Virus(HDV).
There is currently no known treatment for this disease.
Virus can mutate to overcome anti-viral treatments that alter a
virus function. This research has proven in animal models that you can
inactivate a virus by depriving it of a host function upon which
it is dependent. When the
host function is lost, the virus cannot survive. To date, the tested virus has
been unable to modify itself to overcome the host deficiency, rendering
the virus no longer infective.
This study will be the first test of the animal and lab successes in humans with HDV disease. If successful, the treatment will not only provide a treatment for those with HDV disease who have no other treatment, but will become a model for treating other viral diseases. |
| INVESTIGATORS | Jeffrey S. Glenn, MD, PhD |
| CO-FUNDERS | TBD |
| INSTITUTION | Stanford
University School of Medicine Division of Gastroenterology and Hepatology CCSR Building, Rm 3115A 269 Campus Drive Palo Alto, CA 94304-5187 |
| STATUS | Currently in
Validation Process Pending completion of Partnership Agreement and completion of funding |
